Q-omics provides the consensus-scored CA13 profile across patient tissues and cancer cell-line models. CA13 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CA13 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, CA13 protein abundance shows 19,834 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, HNSC, and LSCC as cancer lineages where CA13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CA13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CA13 survival associations across molecular data types. CA13 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CA13 RNA expression–survival associations across cancer types. High CA13 expression shows unfavorable associations in UVM, LGG and KIRP, but favorable associations in SKCM, KIRC and UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UVM as the clearest survival context for CA13 RNA expression.
This table summarizes CA13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CA13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CA13 shows lower tumor expression in HNSC, KIRC, BRCA and LUSC and higher tumor expression in THCA and PAAD. The HNSC box plot shows higher CA13 RNA expression in normal versus tumor tissue (log2 FC = −0.923, t-test p < 0.001).
This table shows molecular features associated with CA13 in patient tissues and cancer cell lines. In patient samples, CA13 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CA13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
